The EMA previously granted orphan designation to mavorixafor in WHIM syndrome. In April 2024, mavorixafor received U.S. Food and Drug Administration approval as XOLREMDI , an oral, once-daily ...
Biocon Ltd and its European partner, Zentiva, have received a decentralised procedure ... as per the European Medicines Agency.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback